axatilimab-csfr
| Brand name | Niktimvo |
|---|---|
| Active ingredient | axatilimab-csfr |
| Strength | 9MG/0.9ML (10MG/ML) |
| Dosage form | Injection |
| Route | Intravenous |
| Modality | Biologic |
| FDA approval | June 2026 |
| Marketing status | Rx |
Source: FDA Purple Book, layered on the CliffBio company graph. Cliff dates are the projected — 12-year biologic exclusivity estimate; estimates are projections, not legal advice.